SUMMARY Several studies have demonstrated the beneficial effect of azathioprine in rheumatoid arthritis. But fears have been expressed about the possible mutagenic and teratogenic effects of prolonged use. If the drug could be withdrawn once remission is achieved, and this remission be then maintained with other agents, the possible complications of long-term therapy might be avoided. A double-blind controlled study was carried out over 8 months in 32 patients receiving long-term azathioprine therapy for rheumatoid arthritis. Substitution of placebo for active drug resulted in clinical deterioration.
Several controlled studies have shown that azathioprine suppresses disease activity in rheumatoid arthritis. 1-3 Since this treatment may not produce a lasting remission, long-term administration can be expected in many instances. The potential adverse effects of prolonged use, including bone marrow suppression, susceptibility to infection, and a tendency to develop malignant tumours, have discouraged its use at an earlier stage of the disease, when it may exert a disease modifying effect.
If azathioprine can be withdrawn once remission has been achieved and this remission then maintained with other agents, long-term therapy and its attendant hazards may be avoided. At present there are insufficient data to ascertain whether this approach is practicable. We report the results of a controlled double-blind study over a period of 8 months on 32 patients with rheumatoid arthritis on long-term azathioprine, when placebo was substituted for the active drug.
Patients and methods
Thirty-two patients were allotted at random to 2 groups; 18 received placebo and 14 continued with azathioprine. The 2 groups were well matched for age, sex, disease duration, serology, and functional capacity. The duration of treatment with azathioprine and details of treatment are given in Table 1 . Most patients required anti-inflammatory agents and analgesics in addition to azathioprine. Twenty-one patients, 12 in the placebo group and 9
Accepted for publication 9 January 1981 Correspondence to Dr M. de Silva. been on azathioprine and 21 on a conmbinationi of azathiopr-ine and gold. Of those on combination therapy placebo was suLbstituted for azathioprine in 12 and 9 continuled on the active drug. Seven patients in the placebo group deteriorated despite continuing on gold, whereas none of the 9 who continued on combination therapy deteriorated.
Discussion
The results of our study, which arc in agreem-iient with a previous study by Hunter ct al., I show that azathioprine continues to exert a beneficial effect in rheumllatoid arthritis over a prolonged period in a small group of patients. Our findings differ from those of Thomas et al., 5 who in a retrospective study of patients with rheumatoid arthritis reported more treatment failures, a diminished steroid-sparing effect and a greater number of toxic reactions, and lowered patient acceptability of azathioprine. Harris et al., I however, found that the steroid-sparing effect of azathioprine persisted 'for some time' after it was discontinued. This evidence was based on a small study.
The timing of the response to azathioprine is unlike that observed with anti-inflammatory agents but resembles more the slow response associated The patients in this study were included in a group of 214 patients treated with cytotoxic drugs over an 11-year period.7 Although neoplasia were more common in this group as a whole, patients on azathioprine had an incidence similar to that of the control population. Our study, like many others, 4 6 confirms a low incidence of adverse effects.
Most patients in this study had been suffering from severe active rheumatoid arthritis requiring treatment with corticosteroids. Gold was used for its steroidsparing effect and azathioprine added, initially in a high dose of 5 mg/kg/day on 5 or 6 days of the week, in the hope that gold toxicity might be reduced.
Some patients had received azathioprine for as long as 12 years. The mean daily dose of azathioprine in our present study was 2 6 mg/kg/day, the drug being administered only on 5 days of the week.
Hunter et al. 4 compared 2 dosage regimens (mean 1I4 mg/kg/day). They found that both half dose (1-1 * 25 mg/kg/day) and full dose (2-2 -5 mg/kg/day) exerted a beneficial effect in severe rheumatoid arthritis. Further studies are required to establish the safest effective dose.
Our results show that in rheumatoid arthritis azathioprine is beneficial in long-term therapy.
Withdrawal results in an exacerbation of disease activity even when patients continue to receive other anti-rheumatic agents, such as gold and nonsteroidal anti-inflammatory drugs. The combination of gold and azathioprine appears to be beneficial in certain patients.
